focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,124.00
Bid: 12,124.00
Ask: 12,128.00
Change: -48.00 (-0.39%)
Spread: 4.00 (0.033%)
Open: 12,180.00
High: 12,188.00
Low: 12,096.00
Prev. Close: 12,172.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: NatWest falls as UK FCA starts criminal action

Tue, 16th Mar 2021 08:50

(Alliance News) - Stock prices in London opened higher on Tuesday tracking global peers, while NatWest was lower after the City watchdog launched criminal proceedings against the state-backed lender.

The FTSE 100 index was up 40.41 points, or 0.6%, at 6,790.11. The mid-cap FTSE 250 index was up 123.33 points, or 0.5%, at 21,645.68. The AIM All-Share index was 0.3% higher at 1,202.98.

The Cboe UK 100 index was up 0.4% at 674.32. The Cboe 250 was up 0.4% at 19,243.66, and the Cboe Small Companies up 0.1% at 13,953.44.

In mainland Europe, the CAC 40 in Paris was up 0.2%, while the DAX 30 in Frankfurt was 0.5% higher.

In the FTSE 100, Barclays was the best performer, up 2.9%, after Credit Suisse raised the UK lender to Outperform from Neutral.

AstraZeneca was up 1.9% after the drugmaker said it has modified an existing agreement with the US government to supply up to 500,000 additional doses of AZD7442, a long-acting antibody combination which is in late-stage development for the prevention and treatment of Covid-19.

In addition, Jefferies raised AstraZeneca to Buy from Hold.

The Anglo-Swedish firm said the new US government deal builds on earlier deals for a total of 200,000 doses with the US Department of Health & Human Service and Department of Defense.

The value of the extended agreement is USD205 million and is contingent on AZD7442 receiving an Emergency Use Authorisation from the US Food & Drug Administration. AstraZeneca said the total value of current agreements with the US government for the development and supply of AZD7442 in 2021 is about USD726 million.

The extended agreement is not anticipated to affect the company's financial guidance for 2021.

AstraZeneca also said it has completed the sale of its 27% stake in Viela Bio Inc to Horizon Therapeutics. It will receive USD775 million in cash proceeds and profit from the Viela stake sale, but this also isn't expected to affect its guidance for 2021.

At the other end of the large-caps, NatWest Group was the worst performer, 1.1% lower after the bank said the UK financial regulator has opened criminal proceedings over the bank's alleged failure to comply with money laundering regulations.

The UK Financial Conduct Authority started the investigation in July 2017 - covering the period from November 2011 to October 2016 - but has now decided to begin criminal proceedings against National Westminster Bank.

NatWest stressed it has been cooperating with the FCA's investigation.

Standard Chartered was down 0.9%, after Credit Suisse downgraded the Asia-focused bank to Underperform from Neutral.

Antofagasta was 0.3% lower despite the Chilean copper miner reporting positive annual results.

For 2020, revenue was up 3.3% to USD5.13 billion from USD4.94 billion in 2019. Pretax profit was USD1.41 billion, up 4.4% from USD1.35 billion.

The company's preferred metric - earnings before interest, tax, depreciation and amortisation - rose 12% to USD2.74 billion in 2020 from USD2.44 billion the year prior.

The miner declared a final dividend of 48.5 cents per share, bringing the total dividend for the year to 54.7 cents per share, up from 17.8 cents in 2019.

The Japanese Nikkei 225 index ended up 0.5% on Tuesday. In China, the Shanghai Composite closed up 0.8%, while the Hang Seng index in Hong Kong closed up 0.6%. The S&P/ASX 200 in Sydney finished 0.8% higher.

The pound was quoted at USD1.3838 early Tuesday, down from USD1.3885 at the London equities close Monday.

The euro was priced at USD1.1925, lower from USD1.1931. Against the Japanese yen, the dollar was trading at JPY109.15, up from JPY10.08.

Brent oil was priced at USD68.32 a barrel Tuesday morning, lower from USD68.70 late Monday. Gold was trading at USD1,731.45 an ounce, up from USD1,730.28.

The economic events calendar on Tuesday has the ZEW economic sentiment survey for both the eurozone and Germany at 1000 GMT and US retail sales at 1230 GMT.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
12 May 2024 13:25

Pfizer and AstraZeneca announce new investments of nearly $1 billion in France

PARIS, May 12 (Reuters) - Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year's annual 'Choose France' business summit.

Read more
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.